New treatments for dementia. Myth, magic, and science

Dementia could affect 778,000 Canadians by the year 2031. While current treatment is mainly supportive, a race to find new treatments for this dreaded disease takes varied approaches and currently accounts for 10% of drug company resources. Tacrine is the first drug licensed by the US Food and Drug...

Full description

Saved in:
Bibliographic Details
Published in:Canadian family physician 1994-06, Vol.40, p.1149-1159
Main Authors: Ganesan, R, Standish, T, Molloy, D W, Darzins, P, Orange, J B
Format: Article
Language:English
Subjects:
Acetylcarnitine - therapeutic use
Adult
Aged
Aged, 80 and over
Attitude to Death
Attitude to Health
Canada - epidemiology
Cultural Characteristics
Dementia
Dementia - classification
Dementia - epidemiology
Dementia - etiology
Dementia - therapy
Drug Approval
Ethics, Medical
Humans
Middle Aged
Nimodipine - therapeutic use
Quality of Life
Social Values
Tacrine - therapeutic use
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dementia could affect 778,000 Canadians by the year 2031. While current treatment is mainly supportive, a race to find new treatments for this dreaded disease takes varied approaches and currently accounts for 10% of drug company resources. Tacrine is the first drug licensed by the US Food and Drug Administration for use in Alzheimer's disease. New treatments raise several ethical issues and involve society's attitude toward death and dying.
ISSN:0008-350X
1715-5258